WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 05/31/20

Deals and Financings MGI Tech of Shenzhen, a company making gene-sequencing machines and related equipment, completed a $1 billion Series B round led by IDG Capital and CPE. The company is a subsidiary of Shenzhen's BGI, China's largest provider of sequencing services. MGI, which wants to of...

SHANGHAI and NEW YORK , May 28, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has been recognized by Life Science Leader for the third year, achieving ...

SHANGHAI and WORCESTER, Mass. , May 19, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and the Worcester Business Development Corporation (WBDC) announced today the successful signing of a land d...

Thermo Fisher Scientific (NYSE: TMO ) will collaborate with WuXi Diagnostics ( OTCPK:WXXWY ) Mayo Clinic to develop a blood test for the detection of IgM and IgG antibodies to the SARS-CoV-2 virus. More news on: Thermo Fisher Scientific Inc., Wuxi Biologics (Cayman) Inc ADR, WuXi Biologi...

SHANGHAI and HOUSTON, April 30, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and Aravive, Inc. (NASDAQ:ARAV), a clinical-stage biopharmaceutical company, today announced a strategic collabo...

WuXi Biologics ( OTCPK:WXXWY ) inks an agreement with Aravive (NASDAQ: ARAV ) aimed at developing high-affinity bispecific antibodies for a target in cancer and fibrosis called CCN2. More news on: Wuxi Biologics (Cayman) Inc ADR, Aravive, Inc., Healthcare stocks news, Read more ...

First GMP facility in WuXi Biologics to use robotic aseptic filling line for biologics Demonstrated diverse and flexible aseptic filling capability while maintaining high-quality and controlled filling accuracy as well as aseptic assurance WUXI, China , April 28, 2020 /PRNewswire/ -...

SHANGHAI and LEVERKUSEN, Germany, April 22, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed the acquisition deal with Bayer for a drug product manufacturing plant...

SUZHOU, China , April 14, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platform, announced that WuXi Biologics (Suzhou) Co., Ltd. has successfully passed its first GMP inspection by the European Medicines Agency...

Wuxi Biologics ADR ( OTCPK:WXXWY ): FY Non-GAAP EPS of RMB0.91; GAAP EPS of RMB0.76. More news on: Wuxi Biologics (Cayman) Inc ADR, WuXi Biologics (Cayman) Inc., Earnings news and commentary, , Read more ...